Dermovate Scalp Application

Steroid responsive dermatoses of the scalp eg, psoriasis & recalcitrant dermatoses.

Apply a small quantity to the scalp at night & morning until improvement is noticeable.

Scalp infection. Dermatoses in childn <1 yr including dermatitis.

Patients w/ history of local hypersensitivity to corticosteroids. W/draw drug gradually if manifestations of hypercortisolism (Cushing's syndrome) & reversible hypothalamic-pituitary-adrenal axis suppression, leading to glucocorticosteroid insufficiency, are observed. Abrupt w/drawal of treatment may result in glucocorticosteroid insufficiency. Risk factors for increased systemic effects are potency & formulation of topical steroid; duration of exposure; application to large surface area; use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings; increasing hydration of stratum corneum; use on thin skin areas eg, face; & on broken skin or other conditions where skin barrier may be impaired. Reports of visual disturbance. Infection risk w/ occlusion. Ensure careful patient supervision if used in psoriasis. Use appropriate antimicrobial therapy in case of infection. Any spread of infection requires w/drawal of topical corticosteroid therapy & administration of appropriate antimicrobial therapy. Instruct patients not to smoke or go near an open flame during application & immediately after use. Min quantity should be used for the shortest duration to achieve desired clinical benefit in patients w/ renal/hepatic impairment. Pregnancy & lactation. Adrenal suppression in childn <12 yr may occur on long-term use. Increased susceptibility to atrophic changes w/ use in childn; limit treatment to only a few days & review wkly.

Pruritus, local skin burning/pain.

Increased systemic exposure w/ CYP3A4 inhibitors (eg, ritonavir & itraconazole).

Topical Corticosteroids

D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.

Rx